Cryopyrin-associated Periodic Syndromes (CAPS) research hub

Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)

This study is testing a new medicine, JTE-162, for people with a rare condition called Cryopyrin-Associated Periodic Syndromes (CAPS). We want to see if it's safe, if people can tolerate it, and if it helps reduce CAPS symptoms. Participants will take the medicine once a day for two weeks.